Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

AlQahtani, 2020
 
NCT04356534
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive
  • inconclusive 33 % decrease in ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
Bajpai M, 2020
 
NCT04346446
RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallyhigh
14/15 inconclusive
  • inconclusive 74 % decrease in off oxygenation (PE) but with a low degree of certainty due to high risk of bias
PlasmAr, 2020
 
NCT04344535
RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
228/105 inconclusive
  • inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
PlasmAr, 2020
 
NCT04344535
RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
228/105 inconclusive
  • inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
Li, 2015
 
ChiCTR2000029757
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
52/51 inconclusive
  • inconclusive 40 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
Duan, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
10/10 inconclusive
    Hegerova, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
    20/20 inconclusive
      Rasheed, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
      21/28 inconclusive
        Sean, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
        39/156 inconclusive
          Joyner, 2020
           
          NCT04338360
          NRaconvalescent plasma treatmentconvalescent plasma treatmentCOVID-19 severe or criticallyserious
          515/561 inconclusive

            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).